Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New UK pancreatic cancer charity to push for timely diagnoses, stronger R&D

This article was originally published in Clinica

Executive Summary

A charity has been set up in the UK which aims to improve the timeliness of pancreatic cancer diagnoses and strengthen research into this high-mortality disease by increasing awareness among the public and the medical community. Pancreatic Cancer Action (PCA) argues that in some 90% of cases, the condition has progressed too far for surgery at the time of diagnosis – for the vast majority (82%) of patients, the condition is untreatable and terminal by then. Average life expectancy from diagnosis is 3-6 months, and five-year survival stands at 3% – a situation that has remained unchanged in over 40 years, says the PCA. In addition, pancreatic cancer is the fifth most common cause of cancer death in the UK, yet receives less than 2% of total research funding, according to the PCA. In 2008, there were 7,780 deaths from the disease and almost 7,700 new diagnoses.

Topics

UsernamePublicRestriction

Register

MT095859

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel